and Caucasian (75%), while 15% of patients were black, and 10% were of other races. Patients were instructed to treat a moderate to severe migraine headache. Two hours after taking one dose of study medication, patients evaluated their headache pain. Associated symptoms of nausea, photophobia, and phonophobia were also evaluated. • In this study, the percentage of patients achieving a pain relief response (mild or no pain) 2 hours after treatment was statistically significantly greater in patients who received AXERT 6.25 mg or 12.5 mg compared with those who received placebo. There was no additional benefit on pain relief provided by the 12.5 mg dose. The 2-hour pain relief results are summarized in Table 4.
Table 4.: Response Rates 2 Hours Following Treatment of Initial Headache in Adolescents age 12-17 years Placebo ALMOTRIP 6.25 mg ALMOTRIP 12.5 mg Study 1 55.3% (n/N = 94/170) 71.8%* (n/N = 127/177) 72.9% † (n/N = 132/181)
Figure 3. Estimated Probability of Achieving an Initial Headache Response (mild or no pain) in 2 Hours in the adolescent study The prevalence of the migraine-associated symptoms (nausea, photophobia, and phonophobia) at 2 hours after taking the dose was not significantly different between patients who received AXERT 6.25 mg or 12.5mg and those who received placebo.
FORM PRICE COMPANY REMARKS IMIGRAN* (Sumatriptan) 50,100 mg Film Coated Tablet -50 mg…2T..16 L.E -100 mg..2T..40 L.E GSK NO-MIGRAIN Z* (Zolmitriptan) 2.5,5 mg Tablet -2.5 mg..2T..18 L.E -5 mg……2T..35 L.E Amoun ZOMIG* (Zolmitriptan) 2.5 mg Tablet -3T….35 L.E Astra Zeneca Launched In 2010 SUMIGRAIN* (Sumatriptan) 25 mg Tablet -2T .... 8 L.E T3A AMIGRAWEST* (Zolmitriptan) 2.5 mg Film Coated Tablet -4T….20 L.E Western Ph.Ind Launched In 2010 RELPAX* (Elytriptan HCL) 40 mg Film Coated Tablet -3T….72 L.E Pfizer Declined In 2011
TRIPTANS MARKET VALUE MAT 3/09 MAT 3/10 MAT 3/11 0 0.5 1 1.5 2 2.5 3 3.5 4 4.5 SALES/MILLIONS
VALUE MARKET SHARE MAT 3/2009 52% 22% 19% 7% IMIGRAN NO-MIGRAIN Z RELPAX SUMIGRAN
VALUE MARKET SHARE MAT 3/2010 44% 28% 17% 8% 3% IMIGRAN NO-MIGRAIN Z ZOMIG SUMIGRAIN AMIGRAWEST
VALUE MARKET SHARE MAT 3/2011 34% 29% 26% 7% 4% AMIGRAN NO-MIGRAIN Z ZOMIG AMIGRAWEST SUMIGRAN
SPECIALITIES-RXS CORELATION SPECIALITIES RXs NUMBER NEUROPSYCH. 11,110 GP 7,386 ENT 3,721 IM 2,940 SURGERY 2,517 CARDIOLOGY 1,021
TRIPTANS RXS ANALYSIS TRIPTAN BRAND RXS NUMBER TARGETED SPEC. ZOMIG* (Zolmitriptan) 20,584 GP,N.P,ENT,IM, SURG., CARD. AMIGRAWEST* (Zolmitriptan) 2,535 NEURO-PSYCH. NO-MIGRAIN Z* (Zolmitriptan) 2,519 GP,NP,ENT SUMIGRAN* (Sumatriptan) 1,596 NP,GP,ENT MEGATAB* (Sumatriptan) 1,352 GYNECHOLOGY IMIGRAN* (Sumatriptan) 1,232 NP,GP,IM,ENT
CLINICAL TRIALS • Crossover, double-blind clinical trial comparing Almotriptan and ergotamine plus caffeine for acute migraine therapy. • Meta Analysis comparative study classifies Almotriptan as one of the best choices for the treatment of migraines.
CLINICAL TRIALS • ALMOTRIPTAN Vs oral SUMATRIPTAN in Abortive treatment of Migraine. • Efficacy and tolerability of Almotriptan versus Zolmitriptan for the acute treatment of menstrual migraine • Almotriptan and Zolmitriptan in the acute treatment of migraine.
- Fall '17